This study evaluates the relationship between alterations in the GI microbiome and GI inflammation on symptom burden in women with breast cancer receiving chemotherapy.
No linked publications found in PubMed
Inclusion Criteria: * Female with a new diagnosis of breast cancer (stage I-III) * Age 20 or older * Able to read and write in English * Chemotherapy naive and beginning the first cycle of moderately or highly emetogenic chemotherapy (For example, Taxotere + cyclophosphamide treatment +/- trastuzumab). Patients who have not received chemotherapy for five years or more are considered chemotherapy naive Exclusion Criteria: * Metastatic disease * Cognitive impairment, based on clinician assessment, that would prevent completing measures * Concurrent radiation therapy or radiation therapy within the last three months * GI co-morbidities (i.e., irritable bowel syndrome, gastroesophageal reflux disease) or bowel surgery within the last three months * A stoma preventing stool collection from the large intestine (i.e., ileostomy)